Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Constant pattern of relapse in primary central nervous lymphoma patients treated with high-dose methotrexate combinations. A Finnish retrospective study.
Harjama L, Kuitunen H, Turpeenniemi-Hujanen T, Haapasaari KM, Leppä S, Mannisto S, Karjalainen-Lindsberg ML, Lehtinen T, Eray M, Vornanen M, Haapasalo H, Soini Y, Jantunen E, Nousiainen T, Vasala K, Kuittinen O. Harjama L, et al. Among authors: kuitunen h. Acta Oncol. 2015 Jun;54(6):939-43. doi: 10.3109/0284186X.2014.990110. Epub 2015 Mar 11. Acta Oncol. 2015. PMID: 25761092
Promising treatment results with blood brain barrier disruption (BBBD) based immunochemotherapy combined with autologous stem cell transplantation (ASCT) in patients with primary central nervous system lymphoma (PCNSL).
Kuitunen H, Tokola S, Siniluoto T, Isokangas M, Sonkajärvi E, Alahuhta S, Turpeenniemi-Hujanen T, Jantunen E, Nousiainen T, Vasala K, Kuittinen O. Kuitunen H, et al. J Neurooncol. 2017 Jan;131(2):293-300. doi: 10.1007/s11060-016-2293-8. Epub 2016 Oct 17. J Neurooncol. 2017. PMID: 27752883
Case Report: Chemotherapy in Conjunction With Blood-Brain Barrier Disruption for a Patient With Germ Cell Tumor With Multiple Brain Metastases.
Knuutinen O, Kuitunen H, Alahuhta S, Isokangas JM, Sonkajärvi E, Turpeenniemi-Hujanen T, Kuittinen O. Knuutinen O, et al. Among authors: kuitunen h. Clin Genitourin Cancer. 2018 Oct;16(5):e993-e996. doi: 10.1016/j.clgc.2018.05.005. Epub 2018 May 26. Clin Genitourin Cancer. 2018. PMID: 29844007 No abstract available.
Comparison of filgrastim, pegfilgrastim, and lipegfilgrastim added to chemotherapy for mobilization of CD34+ cells in non-Hodgkin lymphoma patients.
Partanen A, Valtola J, Ropponen A, Kuitunen H, Kuittinen O, Vasala K, Ågren L, Penttilä K, Keskinen L, Pyörälä M, Nousiainen T, Selander T, Mäntymaa P, Pelkonen J, Varmavuo V, Jantunen E. Partanen A, et al. Among authors: kuitunen h. Transfusion. 2019 Jan;59(1):325-334. doi: 10.1111/trf.14993. Epub 2018 Nov 19. Transfusion. 2019. PMID: 30450652
Risk of secondary haematological malignancies in patients with follicular lymphoma: an analysis of 1028 patients treated in the rituximab era.
Prusila REI, Sorigue M, Jauhiainen J, Mercadal S, Postila A, Salmi P, Tanhua T, Tikkanen S, Kakko S, Kuitunen H, Pollari M, Nystrand I, Kuusisto MEL, Vasala K, Jantunen E, Korkeila E, Karihtala P, Sancho JM, Turpeenniemi-Hujanen T, Kuittinen O. Prusila REI, et al. Among authors: kuitunen h. Br J Haematol. 2019 Nov;187(3):364-371. doi: 10.1111/bjh.16090. Epub 2019 Jul 3. Br J Haematol. 2019. PMID: 31267514 Free article.
Incidence of solid cancer in patients with follicular lymphoma.
Sorigue M, Prusila REI, Jauhiainen J, Mercadal S, Postila A, Salmi P, Tanhua T, Tikkanen S, Kakko S, Kuitunen H, Pollari M, Nystrand I, Kuusisto MEL, Vasala K, Jantunen E, Korkeila E, Karihtala P, Sancho JM, Turpeenniemi-Hujanen T, Kuittinen O. Sorigue M, et al. Among authors: kuitunen h. Acta Oncol. 2019 Nov;58(11):1564-1569. doi: 10.1080/0284186X.2019.1643918. Epub 2019 Aug 1. Acta Oncol. 2019. PMID: 31368395
48 results